Trusted Press Release Distribution   Join | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Polaris Market Research
www.polarismarketresearch.com
Likhil Gajbhiye
likhil.g@polarismarketresearch.com
1-646-568-9980
30 Wall Street 8th Floor New York City, NY 10005 United States


Bookmark and Share
Geriatric Medicines Market Size Historical Growth, Analysis, Opportunities and Forecast To 2026
The “Geriatric Medicines Market” Report provides a complete decision-making overview including definition, product specifications, market gains, key geographic regions and imminent Geriatric Medicines Market industry peers for 2018-2026.

BriefingWire.com, 9/13/2018 - The Global Geriatric Medicines Market Size is anticipated to reach over USD 1,157.34 billion by 2026 according to a new research published by Polaris Market Research.

Geriatric medicines, also called geriatrics is a division of medicines associated with preventive, clinical, remedial, and social aspects of disease generally amongst people that are aged over 65 years or more. In response to the needs of an aging population, demand for geriatric medicines and appropriate cure has developed rapidly during last decades. The proper medical care for the geriatric patients across the range of ill health conditions includes co-morbid complications such as syncope, cerebral aging, and falls among others.

Request For Sample Of This Research Report @ https://www.polarismarketresearch.com/industry-analysis/global-xerostomia-therapeutics-market/request-for-free-sample

The global geriatric medicines market is majorly driven by the factor including a rise in geriatric populations. According to the Eurostat, the number of people aged 65 years and above is expected reach 141 million by 2050 globally. In addition, the high market growth is expected on account of the increasing occurrence of numerous target disorders in the geriatric population, the demographic modification, the rising trend in lifestyle-associated risk aspects, and the considerably developed access to economic medicine across the developing and emerging regions. Continuous R&D activities commenced by key players and pharmaceutical companies to provide to the patient demand is expected to gain the significant outcomes during the forecast period. Increasing occurrence of chronic ailments, refining healthcare organization in emerging economies, increasing acceptance of medical tourism, government initiatives as well as support to provide timely care, and increasing number of specialty clinics are some of the other factors driving of the geriatric medicines market. However, difficulties associated with drug compatibility, lack of patient involvement in clinical trials, and side effects associated with the medications are the factors hampering the market growth.

The global Geriatric Medicines Market is segmented on the basis of therapeutic category, therapeutic condition, and geography.

On the basis of therapeutic category, the global geriatric medicines market is segmented into Analgesics, Antihypertensive, Statins, Antidiabetics, Proton Pump Inhibitor, Anticoagulant, Antipsychotic, and Antidepressant. Pain as an indication is associated with old age and the middle age population unveils the high occurrence rate of pain related syndromes. Based on current trends and the demand for proper therapy, the market is anticipated to witness high growth for therapeutic conditions during the forecast period. On the basis of therapeutic conditions, the global geriatric medicines market is segmented into Cardiovascular, Arthritis, Neurological, Cancer, Osteoporosis, and Respiratory. In 2017, the cardiovascular disease is estimated to be the dominating segment primarily due to the high proliferation of several cardiac disorders such as coronary artery disease, stroke, and hypertension.

Enquiry Before Buying @ https://www.polarismarketresearch.com/industry-analysis/global-xerostomia-therapeutics-market/inquire-before-buying

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2013 Proserve Technology, Inc.